Gary Vanasse, MD
Replimune, Inc.
4
0
0
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (4)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
James L Gulley, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jason Wu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Shared therapeutic areas:
Brigitte C Widemann, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
loic MONDOLONI
Assistance Publique Hopitaux De Marseille
Shared therapeutic areas:
emilie garrido pradalie
APHM
Shared therapeutic areas:
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Shared therapeutic areas:
Emily Y Chew, M.D.
National Eye Institute (NEI)
Shared therapeutic areas:
Jeong Min Lee, MD
Seoul National University Hospital
Shared therapeutic areas:
Sabine Hazan, MD
ProgenaBiome
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (4)
Showing 4 of 4 trials
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
All 4 trials loaded